Immunotherapy Drugs Market In-Depth Overview of Product Specification, Technology
Checkpoint inhibitors and vaccines are the two major types of immunotherapy drugs analyzed in the report. Of these, checkpoint inhibitors held a larger share in the immunotherapy drugs market, accounting for 66.3% in 2017. Checkpoint inhibitors are the first preference for the treatment of chronic diseases, as they provide better and effective treatment results. These drugs act directly on site of action, without delaying the effect of medicine, and are thus being highly adopted for the treatment of several diseases. Some of the major checkpoint inhibitors brand available in the market are Humira, Rituxan/MabThera, Herceptin, Remicade, and Enbrel. Based on therapy area, the immunotherapy drugs market has been categorized into cancer, autoimmune and inflammatory diseases, and infectious diseases. Of these, autoimmune and inflammatory diseases is expected to be the fastest growing category, at a CAGR of 14.8% during the forecast period.
★
★
★
★
★
64 views • 6 slides
